Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

$28.64

+0.54 (+1.92%)

(As of 03:58 PM ET)

Dianthus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for Dianthus Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 8 have given a buy rating, and 2 have given a strong buy rating for DNTH.

Consensus Price Target

$44.71
56.13% Upside

High Forecast	$58.00
Average Forecast	$44.71
Low Forecast	$36.00

According to the 10 analysts' twelve-month price targets for Dianthus Therapeutics, the average price target is $44.71. The highest price target for DNTH is $58.00, while the lowest price target for DNTH is $36.00. The average price target represents a forecasted upside of 56.13% from the current price of $28.64.

Type	Current Forecast 9/21/23 to 9/20/24	1 Month Ago 8/22/23 to 8/21/24	3 Months Ago 6/23/23 to 6/22/24	1 Year Ago 9/21/22 to 9/21/23
Consensus Rating	Buy	Buy	Buy	N/A
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	N/A
Buy	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$44.71	$44.71	$42.83	N/A
Forecasted Upside	56.13% Upside	80.19% Upside	79.32% Upside	N/A

Get Dianthus Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.

Biden's Successor: The Radical Threat to YOUR Savings! (Ad)

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

DNTH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DNTH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Dianthus Therapeutics Stock vs. The Competition

Type	Dianthus Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.20	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	59.13% Upside	991.63% Upside	6.75% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/12/2024	HC Wainwright 2 of 5 stars	S. Ramakanth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00	+50.72%
8/9/2024	Wedbush 3 of 5 stars		Lower Target	Outperform ➝ Outperform	$38.00 ➝ $36.00	+29.68%
7/26/2024	Baird R W 0 of 5 stars	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+106.48%
6/27/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Stavropoulos Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/11/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Katkhuda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/18/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$34.00 ➝ $51.00	+114.38%
3/22/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$22.00 ➝ $39.00	+22.37%
2/15/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$44.00	+85.19%
10/30/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$45.00	+278.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:28 PM ET.

DNTH Forecast - Frequently Asked Questions

What is Dianthus Therapeutics' forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Dianthus Therapeutics is $44.71, with a high forecast of $58.00 and a low forecast of $36.00.
Should I buy or sell Dianthus Therapeutics stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dianthus Therapeutics in the last year. There are currently 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNTH shares.
Does Dianthus Therapeutics's stock price have much upside?: According to analysts, Dianthus Therapeutics's stock has a predicted upside of 80.19% based on their 12-month stock forecasts.
Has Dianthus Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Dianthus Therapeutics's stock had 1 upgrade by analysts.
What analysts cover Dianthus Therapeutics?: Dianthus Therapeutics has been rated by research analysts at Baird R W, Cantor Fitzgerald, HC Wainwright, Robert W. Baird, and Wedbush in the past 90 days.
Do Wall Street analysts like Dianthus Therapeutics more than its competitors?: Analysts like Dianthus Therapeutics more than other "medical" companies. The consensus rating for Dianthus Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DNTH compares to other companies.